Nitrogen Or Sulfur In Aglycone Moiety Patents (Class 536/17.6)
  • Patent number: 11925680
    Abstract: Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: March 12, 2024
    Assignee: Koranex Capital
    Inventors: Tze Chieh Shiao, Serge Moffett, Serge Mignani, Rene Roy
  • Publication number: 20150148527
    Abstract: A sugar chain-containing polymer that enables targeting to the lesion area of liver fibrosis and is useful for imaging, diagnosis and therapy of liver fibrosis; and a sugar chain-containing polymer complex comprising the polymer as a carrier for an anionic substance useful fix therapy and the like; are provided. The polymer is a sugar chain-containing polymer which is a cationic polymer comprising an amine, which polymer comprises N-acetylglucosamine bound thereto. The polymer preferably has a disulfide bond. The polymer preferably has a structure in which polyethyleneimine is linked via a disulfide bond.
    Type: Application
    Filed: May 27, 2014
    Publication date: May 28, 2015
    Applicants: SOMAR Corp., KOREAN RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Bong Hyun CHUNG, Hirohiko ISE, Toshihiro AKAIKE, Sun-Jung KIM
  • Patent number: 9006468
    Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: April 14, 2015
    Assignee: Dow AgroSciences, LLC.
    Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
  • Publication number: 20150045545
    Abstract: The present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or of a polymer film on the surface of the solid support material. Furthermore, the present invention relates to the use of the sorbent according to the invention for the purification of organic molecules, in particular pharmaceutically active compounds, preferably in chromatographic applications.
    Type: Application
    Filed: September 17, 2012
    Publication date: February 12, 2015
    Inventors: Markus Arendt, Björn Degel, Thomas Schwarz, Gerhard Stumm, Martin Welter
  • Publication number: 20150005245
    Abstract: Sialic acid derivatives of the formula (I) in which the symbols have the definitions stated in the description are suitable as medicaments, more particularly for diseases whose course is influenced by Siglec ligands.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 1, 2015
    Inventors: Reinhard Brossmer, Horst Prescher
  • Patent number: 8871726
    Abstract: The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R1, R2, R3, R4, m and n are as defined in specification. The derivative of the present invention is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor associated with glucose reabsorption of bowel or kidney, and has a good urine glucose excreting effect, thus being useful as a therapeutic agent for treating diabetes and related diseases.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: October 28, 2014
    Assignee: Shanghai Allist Pharmaceuticals, Inc.
    Inventor: Huibing Luo
  • Publication number: 20140309178
    Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.
    Type: Application
    Filed: November 18, 2013
    Publication date: October 16, 2014
    Applicant: LEXICON PHARMACEUTICALS, INC.
    Inventors: Kenneth Gordon CARSON, Nicole Cathleen GOODWIN, Bryce Alden HARRISON, David Brent RAWLINS, Eric STROBEL, Brian ZAMBROWICZ
  • Publication number: 20140295566
    Abstract: A novel ligand conjugate which is effectively utilizable for analyzing a function of a protein; a ligand-supporting object; and a method of analyzing a protein. The ligand conjugate has a structure which comprises: a linker compound having a structure represented by the following General Formula (1): (wherein n and p each is an integer of 0 to 6) in which X is a structure comprising one, two, or three hydrocarbon derivative chains which have an aromatic amino group at the end and may have a carbon-nitrogen bond in the main chain, Y is a hydro-carbon structure containing one or more sulfur atoms, and Z is a straight-chain structure comprising a carbon-carbon bond or carbon-oxygen bond; and a sugar which has a reducing end and is bonded to the linker compound through the aromatic amino group.
    Type: Application
    Filed: May 9, 2014
    Publication date: October 2, 2014
    Applicants: Japan Science and Technology Agency, National University Corporation Kagoshima University
    Inventor: Yasuo SUDA
  • Publication number: 20140255374
    Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.
    Type: Application
    Filed: November 6, 2013
    Publication date: September 11, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventor: Scott Eliasof
  • Patent number: 8828952
    Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: September 9, 2014
    Assignee: Progen Pharmaceuticals Limited
    Inventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond
  • Patent number: 8796229
    Abstract: Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: August 5, 2014
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Geert-Jan Boons, Jun Guo
  • Publication number: 20140171630
    Abstract: Novel synthesis routes for preparation of thiodigalactosides and intermediates are presented. The method includes the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corresponding thiol in situ, which in turn is directly reacted with a 3-azido-galactosyl bromide resulting in the 3,3?-di-azido-thio-di-galactoside before the thiol has a chance to reduce the azido 10 group. Hence, in situ formation of the 3-azido-galactosyl thiol from the thiouronium salt is essential in the synthesis procedure, because any other method that generate the thiol separately results in extensive unwanted azide reduction.
    Type: Application
    Filed: February 20, 2014
    Publication date: June 19, 2014
    Applicant: GALECTO BIOTECH AB
    Inventor: Ulf NILSSON
  • Patent number: 8742080
    Abstract: A process for the preparation of compounds having formula (I) is disclosed, wherein: —R1 is a methoxy or methylthio group; —R2 is a O-glycosyloxy residue. Compounds having formula (I) are prepared by reacting the corresponding precursor having R2?OH and the suitably protected 1-acetyl-glycose.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: June 3, 2014
    Assignee: Indena S.p.A.
    Inventors: Stephen Beszant, Bruno Gabetta
  • Patent number: 8709747
    Abstract: The invention relates to compounds of formula (I) wherein the groups A and B represent independently from each other —CH?CH—, or —C?C—, the terms t, u, v, w represent, independently from each other, values ranging from 0 to 9, the groups Y1 and Y2 can represent independently from each other an alkyl group (linear, branched or substituted) carrying from 1 to 9 carbon atoms, the groups Z1, Z2, Z3, and Z4 can represent independently from each other a chemically reactive group W, such as OH, NH2, SH, the groups Z5 and Z6 represent independently from each other a hydrogen atom, silica nanoparticles functionalized by these compounds, and their use as drugs.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: April 29, 2014
    Assignees: Centre National de la Recherche Scientifique, Universite de Rennes 1, I.N.S.E.R.M. (Institut National de la Sante et de la Recherche Medicale), Universite Montpellier 2 Sciences et Techniques
    Inventors: David Brevet, Laurence Raehm, Mireille Blanchard-Desce, Olivier Mongin, Magali Gary-Bobo-Sable-Teychene, Marcel Garcia, Alain Morere, Jean-Olivier Durand
  • Publication number: 20140031533
    Abstract: A precursor used for labeling hepatocyte receptors and applied to radiotracers for imaging or pharmaceutical compositions for liver cancers is revealed. The precursor is a bifunctional compound. The bifunctional group includes a trisaccharide structure and a diamide dimercaptide (N2S2) ligand. The trisaccharide has high affinity to asialoglycoprotein receptors (ASGPR) on surfaces of hepatocytes while N2S2 ligand reacts with radioisotopes to form neutral complexes. Thus the precursor stays on surfaces of hepatocytes to provide radioisotope labeling or treatment effect of liver cancers.
    Type: Application
    Filed: July 24, 2012
    Publication date: January 30, 2014
    Applicant: ATOMIC ENERGY COUNCIL, INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: SHOW-WEN LIU, YU CHANG, CHENG-FANG HSU, MING-CHE TSAI, TSUNG-HSIEN CHIANG, YUEH-FENG DENG, KUEI-LIN LU, CHIH-YUAN LIN, DA-MING WANG, CHING-YUN LI
  • Publication number: 20140024608
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 23, 2014
    Applicant: METHYLGENE INC.
    Inventors: Robert Deziel, Alain Ajamian
  • Publication number: 20130288986
    Abstract: Described herein is a cyclodextrin containing polymer conjugate.
    Type: Application
    Filed: June 20, 2013
    Publication date: October 31, 2013
    Inventors: Mark E. Davis, Jungyeon Hwang, Tianyi Ke, Ching-jou Lim, Thomas Schluep
  • Patent number: 8536153
    Abstract: The efficient synthesis of phosphatidylinositol mono- to hexa-mannoside (PIM1 to PIM6) is reported. The invention relates to these phosphatidylinositol mono- to hexa-mannosides carrying a linker and a reactive functional group, e.g. the sulfhydryl group, a protein, a fluorescent probe, or a solid phase. The invention further relates to vaccines comprising the PIMs linked to a carrier protein or an antigen.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: September 17, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Siwarutt Boonyarattanakalin, Bernd Lepenies
  • Patent number: 8530448
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: September 10, 2013
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Leonard M. Williams
  • Patent number: 8476413
    Abstract: Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: July 2, 2013
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: Bryce Alden Harrison, Spencer David Kimball, Ross Mabon, David Brent Rawlins
  • Patent number: 8450466
    Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: May 28, 2013
    Assignees: The General Hosptial Corporation, Fluoropharma, Inc.
    Inventors: David R. Elmaleh, Timothy M. Shoup, Hongning Fu
  • Publication number: 20130116203
    Abstract: The present invention provides glucosinolate and isothiocyanate compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.
    Type: Application
    Filed: November 7, 2011
    Publication date: May 9, 2013
    Inventors: Scott R. Rajski, Jared Rae Mays
  • Publication number: 20130065849
    Abstract: The invention relates to compounds of formula (I) wherein the groups A and B represent independently from each other —CH?CH—, or —C?C—, the terms t, u, v, w represent, independently from each other, values ranging from 0 to 9, the groups Y1 and Y2 can represent independently from each other an alkyl group (linear, branched or substituted) carrying from 1 to 9 carbon atoms, the groups Z1, Z2, Z3, and Z4 can represent independently from each other a chemically reactive group W, such as OH, NH2, SH, the groups Z5 and Z6 represent independently from each other a hydrogen atom, silica nanoparticles functionalized by these compounds, and their use as drugs.
    Type: Application
    Filed: December 7, 2010
    Publication date: March 14, 2013
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, UNIVERSITE DE RENNES 1
    Inventors: David Brevet, Laurence Raehm, Mireille Blanchard-Desce, Olivier Mongin, Magali Gary-Bobo-Sable-Teychene, Marcel Garcia, Alain Morere, Jean-Olivier Durand
  • Patent number: 8394774
    Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: March 12, 2013
    Assignee: Dow AgroSciences, LLC.
    Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, Annette V. Brown, Thomas L. Siddall
  • Publication number: 20130035479
    Abstract: The present invention relates to a novel process for the chemical synthesis of ?-(1->6)-linked glucosamine disaccharides of the formula (1) and (intermediate) compounds relating to the process. According to further aspects the invention relates to compositions comprising the compounds and the use of the compounds in the synthesis of disaccharides and medicine.
    Type: Application
    Filed: October 1, 2012
    Publication date: February 7, 2013
    Applicant: OM PHARMA
    Inventor: OM PHARMA
  • Publication number: 20130030162
    Abstract: A new process for extracting and purifying glucosinolates from plant material, preferably broccoli sprouts or seeds is described. An alcoholic extract is adsorbed onto a basic resin and eluted with ammonia. Optionally, the alcoholic extract is passed through an ion-exchange column containing acidic resin prior to the adsorption/elution step.
    Type: Application
    Filed: October 4, 2012
    Publication date: January 31, 2013
    Applicant: DSM IP ASSETS B.V.
    Inventors: Christof WEHRLI, Jan SCHUTZ
  • Publication number: 20120263735
    Abstract: The present invention refers to compounds of formula (I) as useful melanoma vaccines' active ingredients. As a matter of fact, compounds of formula (I) are immunogenic artificial antigens, mimetics of GM3 and GM3 lactone, well known tumor associated antigens (TAAs). In addition, the present invention refers to specific antibodies for compounds of formula (I) which are able to bind to the TAAs. The hereinabove reported compounds and antibodies are therefore potentially useful respectively for the active and passive immunization against tumors overexpressing GM3 ganglioside, in a preferred embodiment melanoma and colon cancer, and for their diagnosis and prognosis.
    Type: Application
    Filed: November 4, 2010
    Publication date: October 18, 2012
    Applicant: AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (Italian Hospital)
    Inventors: Cristina Nativi, Lucio Toma, Barbara Richichi, Carlotta Lunghi
  • Publication number: 20120258043
    Abstract: Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl LeX, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.
    Type: Application
    Filed: April 26, 2012
    Publication date: October 11, 2012
    Applicant: BRACCO SUISSE S.A.
    Inventors: Ramachandran RANGANATHAN, Kondareddiar RAMALINGAM, Radhakrishna PILLAI, Edmund R. MARINELLI, Rolf E. SWENSON
  • Patent number: 8222381
    Abstract: New compounds and methods for the preparation of combinatorial libraries of potentially biologically active compounds are based on monosaccharides of formula I being a derivative of a furanose or pyranose form of a monosaccharide, .
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: July 17, 2012
    Assignee: Alchemia Limited
    Inventors: Michael West, Peter Andrews, Tracie Elizabeth Ramsdale, Wim Meutermans, Giang Thanh Le, Chris Clark, Giovanni Abbenante, Ligong Liu
  • Publication number: 20120165277
    Abstract: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3.
    Type: Application
    Filed: April 26, 2010
    Publication date: June 28, 2012
    Applicant: FORSKARPATENT I SYD AB
    Inventors: Hakon Leffler, Ulf J. Nilsson, Henrik Von Wachenfeldt
  • Publication number: 20120165283
    Abstract: This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them.
    Type: Application
    Filed: March 7, 2012
    Publication date: June 28, 2012
    Inventors: Yoshihiko Kobayashi, Yoshihisa Akiyama, Takeshi Murakami, Nobuto Minowa, Masaki Tsushima, Yukiko Hiraiwa, Shoichi Murakami, Mitsuhiro Abe, Kazushige Sasaki, Shigeru Hoshiko, Toshiaki Miyake, Yoshiaki Takahashi, Daishiro Ikeda
  • Publication number: 20120137929
    Abstract: There is provided a gallotannic compound, a method of producing a gallotannic compound, a lithographic printing plate coating composition, a lithographic printing plate, a method of producing a lithographic printing plate and a method of printing.
    Type: Application
    Filed: June 11, 2010
    Publication date: June 7, 2012
    Applicant: MYLAN GROUP
    Inventors: My T Nguyen, A. Kha Phan, Quoc Khoi Nguyen, Marc-André Locas
  • Patent number: 8173606
    Abstract: The invention relates to compounds which are polysulfated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: May 8, 2012
    Assignee: Progen Pharmaceuticals Limited
    Inventors: Vito Ferro, Jon Krueger Fairweather, Tomislav Karoli, Ligong Liu
  • Patent number: 8173797
    Abstract: The present invention is directed to new therapeutic compounds isolated from spider venom and methods of using these new compounds. The compounds are sulfated nucleoside derivatives including ribonucleoside mono- and disulfates derived from guanine, adenosine, and cytidine. Some of these compounds are glycosylated or fucosylated bearing one or more sugar residues.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: May 8, 2012
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Jerrold Meinwald, Andrew Edmund Taggi, Frank Clemens Schroeder
  • Publication number: 20120058960
    Abstract: Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 8, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Geert-Jan BOONS, Jun Guo
  • Publication number: 20120045390
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 5, 2003
    Publication date: February 23, 2012
    Applicant: Genentech, Inc.
    Inventors: Frederic J. DeSauvage, William I. Wood, Zemin Zhang
  • Publication number: 20120009669
    Abstract: A bifunctional compound with a monosaccharide and a N2S2 ligand, and more particularly, a bifunctional compound with a N2S2 ligand and aminohexylacetyl galactosamine (ah-GalNAc4) is provided. A method for preparing the bifunctional compound with a monosaccharide and a N2S2 ligand is also provided, including activating a carboxyl group in an organic ligand, reacting the activated carboxyl group with a galactopyranoside through amidation, and then hydrolyzing. The bifunctional compound of the present invention is widely useful in nuclear medicine for preparation of liver imaging agents for assisting in correct diagnosis of diseases.
    Type: Application
    Filed: April 15, 2011
    Publication date: January 12, 2012
    Applicant: Institute of Nuclear Energy Research Atomic Energy Council, Executive Yuan
    Inventors: SHOW-WEN LIU, CHENG-HSIEN LIN, YU CHANG, CHENG-FANG HSU, TSYH-LANG LIN
  • Patent number: 8044029
    Abstract: Disclosed herein are methods for the treatment of autoimmune or immune related diseases or disorders. Also disclosed are methods for treating such autoimmune or immune related diseases or disorders with the administration of sulfatides. Also disclosed herein are methods of treating autoimmune or immune related diseases or disorders by administering an amount of a sulfatide to the body of a patient effective to reduce or prevent the symptoms of the autoimmune or immune related disease or disorder.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: October 25, 2011
    Assignee: Torrey Pines Institute for Molecular Studies
    Inventor: Vipin Kumar Chaturvedi
  • Publication number: 20110224156
    Abstract: The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).
    Type: Application
    Filed: March 8, 2011
    Publication date: September 15, 2011
    Inventors: Mark A. Wolf, Keith D. Barnes
  • Publication number: 20110190227
    Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists Of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
    Type: Application
    Filed: July 2, 2009
    Publication date: August 4, 2011
    Applicant: Amira Pharmaceuticals, Inc.
    Inventors: John Howard Hutchinson, Thomas Jon Seiders, Bowei Wang, Jeannie M. Arruda, Brian Andrew Stearns, Jeffrey Roger Roppe
  • Publication number: 20110130553
    Abstract: Novel synthesis routes for preparation of thiodigalactosides and intermediates are presented. The method includes the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corresponding thiol in situ, which in turn is directly reacted with a 3-azido-galactosyl bromide resulting in the 3,3?-di-azido-thio-di-galactoside before the thiol has a chance to reduce the azido 10 group. Hence, in situ formation of the 3-azido-galactosyl thiol from the thiouronium salt is essential in the synthesis procedure, because any other method that generate the thiol separately results in extensive unwanted azide reduction.
    Type: Application
    Filed: May 18, 2009
    Publication date: June 2, 2011
    Inventor: Ulf Nilsson
  • Publication number: 20110130354
    Abstract: The invention relates to compounds which are polysulfated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.
    Type: Application
    Filed: December 3, 2010
    Publication date: June 2, 2011
    Applicant: Progen Pharmaceuticals Limited
    Inventors: Vito Ferro, Jon Krueger Fairweather, Tomislav Karoli, Ligong Liu
  • Publication number: 20110130554
    Abstract: A process for the preparation of compounds having formula (I) is disclosed, wherein: —R1 is a methoxy or methylthio group; —R2 is a O-glycosyloxy residue. Compounds having formula (I) are prepared by reacting the corresponding precursor having R2=OH and the suitably protected 1-acetyl-glycose.
    Type: Application
    Filed: April 9, 2009
    Publication date: June 2, 2011
    Applicant: INDENA S.P.A.
    Inventors: Stephen Beszant, Bruno Gabetta
  • Publication number: 20110028702
    Abstract: 13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthrcyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthrcyclines wherein the reduction reaction is maintained at temperatures of about 55° C. to 64° C. without stirring or agitation. The reaction is completed with the addition of aqueous bicarbonate which forms the 13-deoxyanthracycline and precipitates. The precipitates are filtered and the precipitate and filtrate are extracted separately with organic solvents. The crude 13-deoxy anthracycline can be converted to 5-imino-13-deoxy anthracycline by reaction with methanolic ammonia. The reaction can also be performed with an acidic pyridinium salt instead of a strong acid so that neutralization of the reaction or extraction of the product is not necessary, thereby facilitating purification.
    Type: Application
    Filed: August 5, 2010
    Publication date: February 3, 2011
    Applicant: Gem Pharmaceuticals, LLC
    Inventors: Gerald M. Walsh, Richard D. Olson
  • Publication number: 20100279958
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.
    Type: Application
    Filed: April 2, 2010
    Publication date: November 4, 2010
    Applicant: GlycoMimetics, Inc.
    Inventors: John L. MAGNANI, John T. Patton, JR., Leonard M. Williams
  • Publication number: 20100240878
    Abstract: The present invention relates to improved fluorescently labeled monosaccharide and low molecular weight oligosaccharide conjugates for immunofluorescent staining, confocal microscopic imaging and flow cytometry/fluorescence activated cell sorting (FACS). These fluorophore conjugates target cells, components of cell surfaces and extracellular components; and are useful as probes for tumor targeting and cellular uptake.
    Type: Application
    Filed: March 20, 2009
    Publication date: September 23, 2010
    Inventor: Donald L. Barbeau
  • Publication number: 20100221358
    Abstract: The invention relates to novel synthetic derivatives of ?-glycolipids and uses thereof as immunomodulators. More particularly, the invention relates to synthetic derivatives of ?-glycolipids, specifically, the compounds of any one of Formula I, II III and IV or any mixture or combination thereof, and particularly the ALIB-97 (Formula II) derivative and uses thereof for the treatment of different pathologic disorders, particularly, immune-related hepatic disorders and pathologies associated with the metabolic syndrome.
    Type: Application
    Filed: October 13, 2009
    Publication date: September 2, 2010
    Inventors: Yaron Ilan, Arie Dagan
  • Patent number: 7772430
    Abstract: Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical compositions for the treatment of diseases associated to a pathologic activity and/or an over-expression of metalloproteinases, and of cosmetic preparations having anti-ageing properties in particular for hair and skin.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: August 10, 2010
    Assignee: Protera S.R.L.
    Inventors: Ivano Bertini, Marco Fragai, Mauro Lo Conte, Claudio Luchinat, Cristina Nativi, Chiara Venturi
  • Publication number: 20100184711
    Abstract: The present invention relates to stereoselective methods for the preparation of ?-glycosyl thiols and ?-S-linked glycosylceramides.
    Type: Application
    Filed: December 22, 2009
    Publication date: July 22, 2010
    Applicant: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
    Inventors: Xiangming Zhu, Ravindra T. Dere
  • Publication number: 20100184607
    Abstract: A monosaccharide compound of formula I as shown in the specification. Processes for the preparation of the compound of formula I and methods of screening for antibacterial or antibiotic compounds involving the compound of formula I.
    Type: Application
    Filed: August 1, 2008
    Publication date: July 22, 2010
    Applicant: Alchemia Pty Ltd.
    Inventors: Michael Leo West, Wim Meutermans, George Adamson, Karl Schafer, Darren Schliers